Access to Medicines in Low- and Middle-Income Countries – Is the agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) to blame?
DOI:
https://doi.org/10.38159/q1zweb53Keywords:
Trade-Related Aspects of Intellectual Property Rights (TRIPS), access to medicines (ATM), Low and Middle-Income Countries (LMICs)Abstract
This paper argues that the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement is not solely responsible for the lack of access to medicines (ATM) in Low and Middle-Income Countries (LMICs). ATM is a complex global health governance issue influenced by various factors, including intellectual property laws, trade agreements, domestic policies, and manufacturing capacity.
While the TRIPS Agreement provides flexibilities to address public health concerns, such as compulsory licensing and parallel imports, their effective implementation is hindered by several challenges. This paper emphasizes the need for a multifaceted approach to address ATM, involving domestic policy reforms, international cooperation, and investment in domestic manufacturing capacity. By leveraging these strategies, LMICs can enhance access to essential medicines and improve health outcomes for their populations.
Downloads
References
Antony Taubman, Jayashreel Watal (eds), A Handbook on the WTO TRIPS Agreement , 2nd ed., 105-125, 105 Cambridge University Press (2020).
Article 33 of TRIPS Agreement.
Article 66.1 of TRIPS Agreement.
Carlos M. Correa and Reto M. Hilty, eds, Access to Medicines and Vaccines Implementing Flexibilities Under Intellectual Property Law, 8-9, (2022) https://doi.org/10.1007/978-3-030-83114-1
Constitution of the World Health Organization @ https://apps.who.int/gb/gov/assets/constitution-en.pdf (The WHO Constitution was adopted in New York by the International Health Conference held from 19th June to 22nd
July, 1946. It entered into force on 7th April, 1948)
David P. Fidler, The Challenges of Global Health Governance, Council on Foreign Relations (2010) @ http://www.jstor.com/stable/resrep24171(Date Accessed: 31st May 2024)
Dhaval Chudasama, Importance of IntellectualProperty Rights, Journal of Intellectual Property Rights Law.2021; 4(2): 16–22p DOI: 10.37591/JIPRL
Frederick M. Abbott, Thomas Cottier and Francis Gurry, International Intellectual Property in an Integrated World Economy, 3rd edn, Aspen Publishers (2015)
Hang Bing, TRIPS-plus Rules in International Trade Agreements and Access to Medicines Chinese Perspectives and Practices, Global Development Policy Center, 1-8, Boston University (2021) @https://www.bu.edu/gdp/files/2021/04/GEGI_WP__Bing_FIN.pdf (Date Accessed: 1st June, 2024)
Hoen, E, Protection of Clinical Test Data and Public Health: A Proposal to End the Stronghold of Data Exclusivity. In: Correa, C.M., Hilty, R.M. (eds) Access to Medicines and Vaccines. Springer, Cham (2022) @ https://doi.org/10.1007/978-3-030-83114-1 @ (Date Accessed: 2nd June, 2024)
Global Commission on HIV and the Law (2011), Fact Sheet: Intellectual Property Rights and Access to Medicines @ https://hivlawcommission.org/wp-content/uploads (Date Accessed: 17th July, 2024).
Khachigian, L. M., Pharmaceutical patents: Reconciling the Human Right to Health with the Incentive to Invent, Drug Discovery Today (2020), 25(7), 1135-1141. https://doi.org/10.1016/j.drudis.2020.04.009 (Date Accessed: 30th May, 2024)
Lawrence Gostin, Global Health Law, 270-301, 290, Havard University Press (2014).
Motari, M., Nikiema, JB., Kasilo, O.M.J. et al. The Role of Intellectual Property Rights on Access to Medicines in the WHO African Region: 25 years after the TRIPS Agreement. BMC Public Health 21, 490 (2021) https://doi.org/10.1186/s12889-021-10374-y (Date Accessed: 2nd June, 2024)
Ozawa, S., Shankar, R., Leopold, C., & Orubu, S. (2019). Access to medicines through health systems in low- and middle-income countries. Health Policy and Planning, 34(Suppl 3), iii1. https://doi.org/10.1093/heapol/czz119
Paragraph 4 of Doha Declaration Richard Elliot, Access to Medicines for All: WTO Rules, the Human Right to Health and the Hierarchy of International Law (2006) Available @ http://ssrn.com/abstract=2693384 (Links to an external site.) (Date Accessed: 30th May, 2024)
Subhan, J., Scrutinized: The TRIPS Agreement and Public Health, McGill Journal of Medicine : MJM, 9(2), 152-159 (2006) @ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2323529/ (Date Accessed: 29th May 2024)
Saha, C. N., & Bhattacharya, S., Intellectual property rights: An overview and implications in pharmaceutical industry. Journal of Advanced Pharmaceutical Technology & Research, 2(2), 88-93 (2011). https://doi.org/10.4103/2231-4040.82952
Shaikh, O.H. (2016). Test Data Exclusivity in FTAs and Access to Originator Pharmaceuticals. In: Access to Medicine Versus Test Data Exclusivity. Munich Studies on Innovation and Competition, vol 4. Springer, Berlin, Heidelberg.
https://doi.org/10.1007/978-3-662-49655-8_7
Subhan, J., supra, n. 13
The European Commission, Benefits of Intellectual Property Rights @ https://policy.trade.ec.europa.eu/enforcement-and-protection/protecting-eu-creationsinventions-and-designs/benefits-ipr_en (Date Accessed: 18th July, 2024)
UN, SDGs, Goal 3 and Target 3.5 of SDGs @ https://www.globalgoals.org/goals/3-goodhealth-and-well-being/ (Date Accessed: 31st May, 2024)
United Nations (2022), The Role of Intellectual Property Rights in Promoting Africa’s Development @ https://www.un.org/osaa/sites/www.un.org.osaa/files/final_policy_paper_on_iprs_in_afr
ica_fin_en_230822_v56883.pdf (Date Accessed: 18th July, 2024)
WHO, WHO Model List of Essential Medicines - Technical Document @ https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.02 (Date Accessed: 31st May, 2024)
William W. Fisher and Cyrill P. Rigamonti, The South Africa AIDS Controversy: A Case Study in Patent Law and Policy, (10th February, 2005), Harvard Law School The Law and Business of Patents @ https://cyber.harvard.edu/people/tfisher/South%20Africa.pdf
Wirtz VJ, Kaplan WA, Kwan GF, Laing RO., Access to Medications for Cardiovascular Diseases in Low- and Middle-Income Countries, Circulation, 24;133(21):2076-85(2016). PMCID: PMC4880457 @ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4880457/ (Date Accessed: 1st June, 2024)
WTO, Trips Agreement, Article 39.2
Yenet A, Nibret G, Tegegne BA. Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review. Clinicoecon Outcomes Res. 15: 443-458 (2023) doi: 10.2147/CEOR.S413546 (Date Accessed: 30th May, 2024)
Zuma SM, Modiba LM. Challenges associated with provision of essential medicines in the Republic of South Africa and other selected African countries. World J Pharm Res.,8:1532–1547 (2019). doi: 10.20959/wjpr20199-15303 (Date Accessed: 30th May, 2024)
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Bedima Duut (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
